Search Results - caren+freel+meyers

3 Results

Sort By:

Polymer of Prodrug Methods for Sustained Release of Antivirals for Treatment or Prevention of HIV

Unmet Need:Human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) are amongst the most serious and challenging health problems in the world. There are nearly 37 million people worldwide living with HIV/AIDS and approximately 1 million AIDS-related deaths have occurred in 2017 alone - about 5,000 new infections per...

Published: 5/9/2024 | Inventor(s): Caren Freel Meyers, Steven Rannard, Andrew Owen, Kartik Temburnikar, Lauren Coco, Stephanie Henriquez, Faye Hern, Chung Liu, Anika Shakil, Megan Neary

Keywords(s): Disease Indication, HIV, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics

Category(s): Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Activators of Myosin II for Modulating Cell Mechanics

C12770: Novel Panel of Myosin II Activators for Disease Therapy and Tissue EngineeringNovelty:A panel of myosin II activators developed to treat disease and useful for tissue engineering in regenerative medicine.Value Proposition:Changes in cellular mechanics due to impaired activity of myosin II, a motor protein essential for cell division, motility,...

Published: 5/9/2024 | Inventor(s): Douglas Robinson, Alexandra Surcel, Win Pin Ng, Caren Freel Meyers

Keywords(s): Agonists/Promoters, Cancers, Disease Indication, Non-novel, Pancreatic Cancer, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Medical Devices > Regenerative Medicine, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Novel inhibitors of DXP synthase as anti-infective drugs

Invention novelty: novel class of chemical inhibitors targeting DXP synthase with increased selectivity to pathogens Value Proposition: Development of anti-infectives has direct impact on infectious diseases such as malaria and tuberculosis. The long term goal is to develop novel, potent and broad-based anti-microbial agents that also exhibit limited...

Published: 5/9/2024 | Inventor(s): Caren Freel Meyers, Francine Morris, Ryan Vierling

Keywords(s): Antagonists/Inhibitors, Bacterial Infections, Biomarker, Disease Indication, Infectious Diseases, Mechanism-of-action Biomarker, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections